A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Alendronate; Diphosphonates; Ibandronic Acid

Criteria

Inclusion Criteria:

• Ambulatory women

• Diagnosis of post-menopausal osteoporosis

• Women who have never received bisphosphonate therapy, or who have discontinued daily bisphosphonates at least 3 months prior to study entry

Exclusion Criteria:

• Inability to stand or sit in the upright position for greater than or equal to 60 minutes

• Allergy to bisphosphonates;

• Previous or current treatment with weekly or monthly bisphosphonates, or daily bisphosphonates for the last 3 months prior to study entry